Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radium-223 plus exemestane and everolimus in HER2-negative HR-positive breast cancer with bone metastases
CTR20150753Phase 2Terminated
- Sponsor
- Bayer
- Start
- Mar 2016
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in breast cancer, sponsored by Bayer. Started Mar 2016; status: terminated.
02
Drugs
radium-223 dichloride
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20150753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150753.